Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jane Huang

Showing results (81-90 of 126) with videos related to

Pageof 13
Sort By:
Environmental Toxicology|November 16, 2017
Oolong tea prevents cardiomyocyte loss against hypoxia by attenuating p-JNK mediated hypertrophy and enhancing P-IGF1R, p-akt, and p-Bad<sup>ser136</sup> activity and by fortifying NRF2 antioxidation systemMarthandam Asokan Shibu, Chia-Hua Kuo, Bih-Cheng Chen, et al.
Journal of Medicinal Chemistry|November 30, 2004
Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agentsTodd R Elworthy, Emma R Brill, San-San Chiou, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugsJian Jeffrey Chen, Nolan Dewdney, Xiaohong Lin, et al.
Molecular Therapy. Nucleic Acids|December 17, 2017
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc<sub>3</sub>-Conjugated 2'-MOE-ASOsColby S Shemesh, Rosie Z Yu, Mark S Warren, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2019
A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening ProgramAlain Tremblay, Niloofar Taghizadeh, Jane Huang, et al.
Blood Advances|October 12, 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphomaHaiyan Yang, Bing Xiang, Yuqin Song, et al.
Journal of Hematology & Oncology|May 13, 2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studyWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Pageof 13

Showing results (81-90 of 126) with videos related to

Sort By:
Pageof 13
Environmental Toxicology|November 16, 2017
Oolong tea prevents cardiomyocyte loss against hypoxia by attenuating p-JNK mediated hypertrophy and enhancing P-IGF1R, p-akt, and p-Bad<sup>ser136</sup> activity and by fortifying NRF2 antioxidation systemMarthandam Asokan Shibu, Chia-Hua Kuo, Bih-Cheng Chen, et al.
Journal of Medicinal Chemistry|November 30, 2004
Lactams as EP4 prostanoid receptor agonists. 3. Discovery of N-ethylbenzoic acid 2-pyrrolidinones as subtype selective agentsTodd R Elworthy, Emma R Brill, San-San Chiou, et al.
Blood Advances|April 7, 2022
Zanubrutinib monotherapy in relapsed/refractory indolent non-Hodgkin lymphomaTycel Phillips, Henry Chan, Constantine S Tam, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Bioorganic & Medicinal Chemistry Letters|November 1, 2003
Design and synthesis of orally active inhibitors of TNF synthesis as anti-rheumatoid arthritis drugsJian Jeffrey Chen, Nolan Dewdney, Xiaohong Lin, et al.
Molecular Therapy. Nucleic Acids|December 17, 2017
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc<sub>3</sub>-Conjugated 2'-MOE-ASOsColby S Shemesh, Rosie Z Yu, Mark S Warren, et al.
Ejhaem|February 23, 2023
Zanubrutinib in patients with treatment-naïve or relapsed/refractory Waldenström macroglobulinemia: An expanded-access study of 50 patients in the United StatesJorge J Castillo, Edwin C Kingsley, Mohit Narang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2019
A Randomized Controlled Study of Integrated Smoking Cessation in a Lung Cancer Screening ProgramAlain Tremblay, Niloofar Taghizadeh, Jane Huang, et al.
Blood Advances|October 12, 2021
Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphomaHaiyan Yang, Bing Xiang, Yuqin Song, et al.
Journal of Hematology & Oncology|May 13, 2020
Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter studyWei Xu, Shenmiao Yang, Keshu Zhou, et al.
Pageof 13